questionsmedicales.fr
Bactéries
Proteobacteria
Gammaproteobacteria
Vibrionaceae
Vibrio
Vibrio cholerae
Vibrio cholerae : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Choléra
Diagnostic microbiologique
Tests de diagnostic
Vibrio cholerae
Période d'incubation
Choléra
Symptômes
5
Choléra
Portage asymptomatique
Traitements
5
Traitement du choléra
Réhydratation
Efficacité du traitement
Choléra
Facteurs de risque
5
Facteurs de risque
Choléra
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae : Questions médicales les plus fréquentes",
"headline": "Vibrio cholerae : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Vibrio cholerae : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-28",
"dateModified": "2025-04-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Vibrio",
"url": "https://questionsmedicales.fr/mesh/D014733",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio",
"code": {
"@type": "MedicalCode",
"code": "D014733",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae non-O1",
"alternateName": "Vibrio cholerae non-O1",
"url": "https://questionsmedicales.fr/mesh/D044163",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae non-O1",
"code": {
"@type": "MedicalCode",
"code": "D044163",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100.075"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae O1",
"alternateName": "Vibrio cholerae O1",
"url": "https://questionsmedicales.fr/mesh/D041241",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae O1",
"code": {
"@type": "MedicalCode",
"code": "D041241",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100.151"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vibrio cholerae O139",
"alternateName": "Vibrio cholerae O139",
"url": "https://questionsmedicales.fr/mesh/D041242",
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae O139",
"code": {
"@type": "MedicalCode",
"code": "D041242",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B03.660.250.830.830.100.200"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Vibrio cholerae",
"alternateName": "Vibrio cholerae",
"code": {
"@type": "MedicalCode",
"code": "D014734",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Firdausi Qadri",
"url": "https://questionsmedicales.fr/author/Firdausi%20Qadri",
"affiliation": {
"@type": "Organization",
"name": "Infectious Diseases Division, icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh."
}
},
{
"@type": "Person",
"name": "Munirul Alam",
"url": "https://questionsmedicales.fr/author/Munirul%20Alam",
"affiliation": {
"@type": "Organization",
"name": "International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh."
}
},
{
"@type": "Person",
"name": "Shanta Dutta",
"url": "https://questionsmedicales.fr/author/Shanta%20Dutta",
"affiliation": {
"@type": "Organization",
"name": "National Institute of Cholera and Enteric Diseases, NICED-JICA Building, 57 Dr. S.C. Banerjee Road, Beliaghata, Kolkata, 700 010, India."
}
},
{
"@type": "Person",
"name": "Shelley M Payne",
"url": "https://questionsmedicales.fr/author/Shelley%20M%20Payne",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Biosciences and LaMontagne Center for Infectious Diseases, The University of Texas at Austin, Austin, Texas, USA payne@utexas.edu."
}
},
{
"@type": "Person",
"name": "Bibhuti Bhusan Pal",
"url": "https://questionsmedicales.fr/author/Bibhuti%20Bhusan%20Pal",
"affiliation": {
"@type": "Organization",
"name": "Microbiology Division, ICMR-Regional Medical Research Centre, Chandrasekharpur, Bhubaneswar, 751023, Orissa, India. Electronic address: bbpal_rmrc@yahoo.co.in."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Budget impact analysis of biosimilar natalizumab in the US.",
"datePublished": "2024-07-01",
"url": "https://questionsmedicales.fr/article/38995822",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.37765/ajmc.2024.89558"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effects of a global budget payment scheme on medical specialty workforces.",
"datePublished": "2022-08-09",
"url": "https://questionsmedicales.fr/article/35973242",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.socscimed.2022.115254"
}
},
{
"@type": "ScholarlyArticle",
"name": "Budget impact analysis of daratumumab for light-chain amyloidosis in Cyprus.",
"datePublished": "2023-02-12",
"url": "https://questionsmedicales.fr/article/36709051",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/14737167.2023.2174972"
}
},
{
"@type": "ScholarlyArticle",
"name": "Paediatric clinical trials need paediatric clinical trial budgets.",
"datePublished": "2023-05-10",
"url": "https://questionsmedicales.fr/article/37119385",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/apa.16808"
}
},
{
"@type": "ScholarlyArticle",
"name": "White House budget includes push to eliminate hepatitis C.",
"datePublished": "2023-03-16",
"url": "https://questionsmedicales.fr/article/36926977",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1126/science.adh7975"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Bactéries",
"item": "https://questionsmedicales.fr/mesh/D001419"
},
{
"@type": "ListItem",
"position": 3,
"name": "Proteobacteria",
"item": "https://questionsmedicales.fr/mesh/D020560"
},
{
"@type": "ListItem",
"position": 4,
"name": "Gammaproteobacteria",
"item": "https://questionsmedicales.fr/mesh/D020563"
},
{
"@type": "ListItem",
"position": 5,
"name": "Vibrionaceae",
"item": "https://questionsmedicales.fr/mesh/D014737"
},
{
"@type": "ListItem",
"position": 6,
"name": "Vibrio",
"item": "https://questionsmedicales.fr/mesh/D014733"
},
{
"@type": "ListItem",
"position": 7,
"name": "Vibrio cholerae",
"item": "https://questionsmedicales.fr/mesh/D014734"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Vibrio cholerae - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Vibrio cholerae",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Vibrio cholerae",
"description": "Comment diagnostiquer une infection par Vibrio cholerae ?\nQuels tests sont utilisés pour confirmer le choléra ?\nQuels symptômes indiquent une infection par Vibrio cholerae ?\nQuelle est la période d'incubation du choléra ?\nComment différencier le choléra d'autres diarrhées ?",
"url": "https://questionsmedicales.fr/mesh/D014734?mesh_terms=Budgets#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Vibrio cholerae",
"description": "Quels sont les principaux symptômes du choléra ?\nComment se manifeste la déshydratation dans le choléra ?\nLe choléra peut-il être asymptomatique ?\nQuels signes indiquent une déshydratation sévère ?\nLes symptômes du choléra apparaissent-ils rapidement ?",
"url": "https://questionsmedicales.fr/mesh/D014734?mesh_terms=Budgets#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Vibrio cholerae",
"description": "Comment prévenir l'infection par Vibrio cholerae ?\nLa vaccination contre le choléra est-elle efficace ?\nQuelles mesures d'hygiène sont recommandées ?\nComment l'eau potable peut-elle prévenir le choléra ?\nLes voyages dans des zones à risque nécessitent-ils des précautions ?",
"url": "https://questionsmedicales.fr/mesh/D014734?mesh_terms=Budgets#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Vibrio cholerae",
"description": "Quel est le traitement principal du choléra ?\nLes antibiotiques sont-ils nécessaires pour le choléra ?\nComment prévenir la déshydratation dans le choléra ?\nQuels médicaments sont utilisés pour traiter le choléra ?\nLe traitement du choléra est-il efficace ?",
"url": "https://questionsmedicales.fr/mesh/D014734?mesh_terms=Budgets#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Vibrio cholerae",
"description": "Quelles sont les complications possibles du choléra ?\nLe choléra peut-il entraîner la mort ?\nComment la déshydratation affecte-t-elle le corps ?\nQuelles sont les conséquences à long terme du choléra ?\nLe choléra peut-il causer des épidémies ?",
"url": "https://questionsmedicales.fr/mesh/D014734?mesh_terms=Budgets#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Vibrio cholerae",
"description": "Quels sont les facteurs de risque du choléra ?\nLes enfants sont-ils plus à risque de choléra ?\nComment la malnutrition influence-t-elle le choléra ?\nLes personnes vivant dans des zones urbaines sont-elles à risque ?\nLes voyageurs peuvent-ils être exposés au choléra ?",
"url": "https://questionsmedicales.fr/mesh/D014734?mesh_terms=Budgets#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une infection par Vibrio cholerae ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par culture de selles ou tests PCR pour détecter la bactérie."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer le choléra ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de culture des selles et les tests rapides de détection d'antigènes sont utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une infection par Vibrio cholerae ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent diarrhée aqueuse, vomissements et déshydratation rapide."
}
},
{
"@type": "Question",
"name": "Quelle est la période d'incubation du choléra ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "La période d'incubation est généralement de 1 à 5 jours après l'exposition."
}
},
{
"@type": "Question",
"name": "Comment différencier le choléra d'autres diarrhées ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le choléra se caractérise par une diarrhée aqueuse profuse et une déshydratation rapide."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux symptômes du choléra ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux symptômes sont diarrhée aqueuse, vomissements, crampes abdominales."
}
},
{
"@type": "Question",
"name": "Comment se manifeste la déshydratation dans le choléra ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "La déshydratation se manifeste par soif intense, sécheresse de la peau et fatigue."
}
},
{
"@type": "Question",
"name": "Le choléra peut-il être asymptomatique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines personnes peuvent être porteuses sans présenter de symptômes."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une déshydratation sévère ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent confusion, tachycardie, hypotension et urines très rares."
}
},
{
"@type": "Question",
"name": "Les symptômes du choléra apparaissent-ils rapidement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent apparaître rapidement, souvent dans les 24 heures."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'infection par Vibrio cholerae ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par l'accès à l'eau potable, l'hygiène et la vaccination."
}
},
{
"@type": "Question",
"name": "La vaccination contre le choléra est-elle efficace ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccins peuvent réduire le risque d'infection, surtout en zones à risque."
}
},
{
"@type": "Question",
"name": "Quelles mesures d'hygiène sont recommandées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Se laver les mains fréquemment et consommer des aliments bien cuits sont essentiels."
}
},
{
"@type": "Question",
"name": "Comment l'eau potable peut-elle prévenir le choléra ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'eau potable et propre empêche l'ingestion de Vibrio cholerae, réduisant le risque."
}
},
{
"@type": "Question",
"name": "Les voyages dans des zones à risque nécessitent-ils des précautions ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est conseillé de se faire vacciner et de suivre des mesures d'hygiène strictes."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal du choléra ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est la réhydratation orale ou intraveineuse selon la gravité."
}
},
{
"@type": "Question",
"name": "Les antibiotiques sont-ils nécessaires pour le choléra ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antibiotiques peuvent être utilisés pour réduire la durée de la diarrhée et la gravité."
}
},
{
"@type": "Question",
"name": "Comment prévenir la déshydratation dans le choléra ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La réhydratation rapide avec des solutions de réhydratation orale est essentielle."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour traiter le choléra ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antibiotiques comme la doxycycline ou l'azithromycine sont souvent prescrits."
}
},
{
"@type": "Question",
"name": "Le traitement du choléra est-il efficace ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un traitement rapide et approprié est très efficace pour réduire la mortalité."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles du choléra ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent déshydratation sévère, choc hypovolémique et insuffisance rénale."
}
},
{
"@type": "Question",
"name": "Le choléra peut-il entraîner la mort ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, sans traitement rapide, le choléra peut être mortel en raison de la déshydratation."
}
},
{
"@type": "Question",
"name": "Comment la déshydratation affecte-t-elle le corps ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La déshydratation peut entraîner des déséquilibres électrolytiques et des défaillances organiques."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences à long terme du choléra ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les conséquences peuvent inclure des problèmes de santé persistants, comme des troubles digestifs."
}
},
{
"@type": "Question",
"name": "Le choléra peut-il causer des épidémies ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le choléra peut provoquer des épidémies, surtout dans des conditions d'hygiène précaires."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque du choléra ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'accès limité à l'eau potable, la malnutrition et l'absence d'hygiène."
}
},
{
"@type": "Question",
"name": "Les enfants sont-ils plus à risque de choléra ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les enfants et les personnes âgées sont plus vulnérables aux complications du choléra."
}
},
{
"@type": "Question",
"name": "Comment la malnutrition influence-t-elle le choléra ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "La malnutrition affaiblit le système immunitaire, augmentant le risque d'infection par choléra."
}
},
{
"@type": "Question",
"name": "Les personnes vivant dans des zones urbaines sont-elles à risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les zones urbaines surpeuplées avec un accès limité à l'eau potable sont à risque."
}
},
{
"@type": "Question",
"name": "Les voyageurs peuvent-ils être exposés au choléra ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les voyageurs dans des régions endommagées par le choléra doivent prendre des précautions."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 22/04/2025
Contenu vérifié selon les dernières recommandations médicales
5 publications dans cette catégorie
Affiliations :
Infectious Diseases Division, icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh.
Publications dans "Vibrio cholerae" :
5 publications dans cette catégorie
Affiliations :
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Publications dans "Vibrio cholerae" :
5 publications dans cette catégorie
Affiliations :
National Institute of Cholera and Enteric Diseases, NICED-JICA Building, 57 Dr. S.C. Banerjee Road, Beliaghata, Kolkata, 700 010, India.
Publications dans "Vibrio cholerae" :
4 publications dans cette catégorie
Affiliations :
Department of Molecular Biosciences and LaMontagne Center for Infectious Diseases, The University of Texas at Austin, Austin, Texas, USA payne@utexas.edu.
Publications dans "Vibrio cholerae" :
4 publications dans cette catégorie
Affiliations :
Microbiology Division, ICMR-Regional Medical Research Centre, Chandrasekharpur, Bhubaneswar, 751023, Orissa, India. Electronic address: bbpal_rmrc@yahoo.co.in.
Publications dans "Vibrio cholerae" :
4 publications dans cette catégorie
Affiliations :
Microbiology Division, ICMR-Regional Medical Research Centre, Chandrasekharpur, Bhubaneswar, 751023, Orissa, India. Electronic address: smruti2007rkl@gmail.com.
Publications dans "Vibrio cholerae" :
4 publications dans cette catégorie
Affiliations :
Molecular Genetics Laboratory, Centre for Human Microbial Ecology, Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad 121001, India; School of Life Sciences, Manipal Academy of Higher Education, Manipal 576104, Karnataka, India. Electronic address: bhabatosh@thsti.res.in.
Publications dans "Vibrio cholerae" :
4 publications dans cette catégorie
Affiliations :
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.
Publications dans "Vibrio cholerae" :
4 publications dans cette catégorie
Affiliations :
National Institute of Cholera and Enteric Diseases, NICED-JICA Building, 57 Dr. S.C. Banerjee Road, Beliaghata, Kolkata, 700 010, India.
Publications dans "Vibrio cholerae" :
3 publications dans cette catégorie
Affiliations :
Maryland Pathogen Research Institute, University of Maryland, College Park, MD, 20742, USA.
Institute for Advanced Computer Studies, University of Maryland, University of Maryland, College Park, MD, 20742, USA.
Publications dans "Vibrio cholerae" :
3 publications dans cette catégorie
Affiliations :
Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Division of Global Health, Massachusetts General Hospital for Children, Boston, Massachusetts, USA.
Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
Publications dans "Vibrio cholerae" :
3 publications dans cette catégorie
Affiliations :
Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Publications dans "Vibrio cholerae" :
3 publications dans cette catégorie
Affiliations :
Infectious diseases division, icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh.
Publications dans "Vibrio cholerae" :
3 publications dans cette catégorie
Affiliations :
Infectious diseases division, icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh), Dhaka, Bangladesh.
Publications dans "Vibrio cholerae" :
3 publications dans cette catégorie
Affiliations :
Microbiology Division, ICMR-Regional Medical Research Centre, India.
Publications dans "Vibrio cholerae" :
3 publications dans cette catégorie
Affiliations :
Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA; Department of Microbiology, Harvard Medical School, Boston, MA, USA; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, MA, USA; Howard Hughes Medical Institute, Bethesda, MD, USA. Electronic address: mwaldor@research.bwh.harvard.edu.
Publications dans "Vibrio cholerae" :
3 publications dans cette catégorie
Affiliations :
Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Publications dans "Vibrio cholerae" :
3 publications dans cette catégorie
Affiliations :
National Institute of Cholera and Enteric Diseases, NICED-JICA Building, 57 Dr. S.C. Banerjee Road, Beliaghata, Kolkata, 700 010, India.
Publications dans "Vibrio cholerae" :
3 publications dans cette catégorie
Affiliations :
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences of Okayama University, 1-1-1 Tsushima-naka, Kita-ku, Okayama, Okayama, 700-8530, Japan. Electronic address: k-oka@xd6.so-net.ne.jp.
Publications dans "Vibrio cholerae" :
2 publications dans cette catégorie
Affiliations :
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), 68 Shaheed Tajuddin Ahmed Sarani, Mohakhali, Dhaka 1212, Bangladesh.
Publications dans "Vibrio cholerae" :
Biosimilars provide an opportunity for a more sustainable and cost-effective treatment for multiple sclerosis (MS). This study evaluated the potential financial impact of implementing a formulary chan...
The budget impact of transitioning to biosimilar NTZ for the treatment of relapsing-remitting MS (RRMS) was estimated over a 3-year time horizon based on real-world dosing. Additional scenario analyse...
The target population was estimated from a 1-million-member hypothetical commercial health plan. Model inputs were drug acquisition costs and treatment-related and patient coinsurance costs. Budget im...
Over 3 years, 255 patients were estimated to be treated with high-efficacy disease-modifying therapies for RRMS. The inclusion of biosimilar NTZ onto a formulary would result in cumulative cost saving...
Adoption of biosimilar NTZ can yield considerable cost savings to US health plans that could result in increased treatment access for patients with RRMS....
Containing rising health care costs by a global budget offers promise, but might have unintended effects on the composition of medical specialty workforces. When a budget is given to a group of medica...
The aim of this study is to assess the budget impact of daratumumab for light-chain amyloidosis in Cyprus....
A budget impact model assessed the cost prior and after the introduction of daratumumab for light-chain amyloidosis. All related costs were set from the perspective of Cyprus NHS. Clinical data were e...
The introduction of D-VCd led to a net budget impact of €254,264 in the first year, which escalated to €497,007 by fifth year. The PMPY was estimated at €0.2893 in the first year, reaching €0.5246 at ...
The introduction of daratumumab for AL amyloidosis, with a 90% annual uptake over 5 years, leads to a substantial budget impact. Managed entry agreement schemes can be considered in order to mitigate ...
Clinical trials and the need for new treatments were recently listed among the most important factors for child health. The aim of the present study was to describe some of our experiences with budget...
We selected 10 trials sponsored by the pharmaceutical industry at the Pediatric Clinical Research Center at Sahlgrenska University Hospital in Gothenburg, Sweden. We compared the sponsor's initial bud...
The mean difference in total budget amount between the initial budget and the final budget was +60% (mean 59%, range 31%-139%). The costs for preparation of the clinical trial, time spent for study ac...
Our findings indicate that a substantial part of the trial-related costs would not be covered by the sponsor, had the initial budget been accepted. A thorough review and budget negotiation, as well as...
$11.3 billion would go to treatment, testing, and education....
This article reviews the peer-reviewed and grey literature published from January 1985 to November 2022 that has quantitatively evaluated the effects of personalized budgets for people with disabiliti...
Pharmacoeconomic analyses are an important and useful guide for understanding a pharmacotherapeutic intervention's financial impact for relevant stakeholders. One type of pharmacoeconomic analysis tha...
To analyze the budget impact of upadacitinib (UPA) 15 mg + methotrexate (MTX) for the treatment of moderate-to-severe rheumatoid arthritis (RA) in patients with an inadequate response to conventional ...
A budget impact analysis model was developed for a hypothetical cohort of 100,000 adults with health insurance coverage who were diagnosed with RA over a 5-year time horizon. The model parameters were...
The introduction of UPA 15 mg + MTX for the treatment of moderate-to-severe RA and cDMARD-IR resulted in minimal increase, with a five-year total cumulative incremental cost of USD 1,855 for social se...
The introduction of UPA 15 mg + MTX for the treatment of moderate-to-severe RA and cDMARD-IR can provide an effective treatment option with a minimal increase in costs for the healthcare system in Arg...
Motivation for the study. Rheumatoid arthritis (RA) is a disease that hasn’t cure, so it’s important to know the budget impact of treatment with upadacitinib (UPA) 15 mg + methotrexate (MTX) in patien...
The aim of this study was to estimate the budget impact of adding cabergoline to the Brazilian Unified Health System (SUS) formulary for the treatment of patients with Cushing's disease (CD) who do no...
We conducted a budget impact analysis (BIA) from the perspective of the Brazilian SUS over a 5-year time horizon. We compared two scenarios: ketoconazole (Scenario 1) versus including cabergoline as a...
The total costs were BRL $25,596,729 for Scenario 1 and BRL $32,469,169 for Scenario 2. The budget impact of adding cabergoline to the formulary for CD treatment within the SUS would be BRL $6,091,036...
The estimated budget impact of adding cabergoline to the formulary for CD treatment within the Brazilian SUS would be about BRL $6 million. While cost savings cannot be expected, the budget impact of ...
In many countries, the healthcare sector is dealing with important challenges such as increased demand for healthcare services, capacity problems in hospitals and rising healthcare costs. Therefore, o...
A budget impact analysis was conducted to estimate the actual costs and reimbursement of aCTG performed in midwife-led care and obstetrician-led care (ie, base-case analysis) from the Dutch healthcare...
Shifting aCTG from obstetrician-led care to midwife-led-care would increase actual costs with €311 763 (97.5% CI €188 574 to €426 072) and €1 247 052 (97.5% CI €754 296 to €1 704 290) for implementati...
From the Dutch healthcare perspective, we estimated that implementing aCTG in midwife-led care may increase the associated actual costs. At the same time, it might lower the healthcare reimbursement....